Mirum Pharmaceuticals president sells $152,256 in stock

Prior to this transaction, Radovich acquired 5,750 shares of common stock on January 23, 2025, through the vesting of restricted stock units. These units were acquired at no cost, as each restricted stock unit represents a contingent right to receive one share of common stock.After the sale, Radovich's direct ownership in Mirum Pharmaceuticals (NASDAQ:MIRM) stands at 29,588 shares. The shares sold were intended to cover tax withholding obligations associated with the vesting of restricted stock units. The $2.33 billion market cap company maintains strong liquidity with a current ratio of 3.34 and has demonstrated remarkable growth with revenue increasing 112.14% over the last twelve months. Discover more comprehensive insights about MIRM and access detailed financial analysis through InvestingPro's exclusive research reports. The $2.33 billion market cap company maintains strong liquidity with a current ratio of 3.34 and has demonstrated remarkable growth with revenue increasing 112.14% over the last twelve months. Discover more comprehensive insights about MIRM and access detailed financial analysis through InvestingPro's exclusive research reports.

Prior to this transaction, Radovich acquired 5,750 shares of common stock on January 23, 2025, through the vesting of restricted stock units. These units were acquired at no cost, as each restricted stock unit represents a contingent right to receive one share of common stock.

After the sale, Radovich's direct ownership in Mirum Pharmaceuticals stands at 29,588 shares. The shares sold were intended to cover tax withholding obligations associated with the vesting of restricted stock units.

In other recent news, Mirum Pharmaceuticals has been making significant strides in its business operations. The company recently announced its preliminary and unaudited 2024 financial results, surpassing its sales guidance with net product sales of approximately $336 million. Notably, Mirum Pharmaceuticals also projects global net product sales for 2025 to reach between $420 million and $435 million.

Mirum Pharmaceuticals has also made advancements in its clinical programs, such as the VISTAS study of volixibat, expected to complete enrollment in the second half of 2025. The company's financial strength is evident in its year-end cash balance of roughly $287 million, reflecting its commercial success.

H.C. Wainwright's analyst reiterated a Buy rating on Mirum, following the company's strong sales results. In addition, the company has expanded the use of its drug LIVMARLI and reported positive interim results for its volixibat treatments in cholestatic diseases. These recent developments highlight Mirum Pharmaceuticals' potential for continued growth in the rare disease sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.